Aquestive therapeutics, inc. (AQST)
Income statement / Yearly
Dec'19Dec'18Dec'17
Revenues

52,609

67,430

-

Revenues

-

-

66,918

Costs and expenses:
The aggregate costs incurred in the production of goods and supply for sale.

20,361

20,988

19,820

Research and development

20,574

23,112

22,133

Selling, general and administrative

64,342

72,269

25,078

Total costs and expenses

105,277

116,369

67,031

Loss from operations

-52,668

-48,934

-113

Other income/(expenses):
Interest expense

9,318

7,711

7,707

Interest income

636

552

0

Loss on the extinguishment of debt

-4,896

0

-

Change in fair value of warrant

0

5,278

1,123

Other expense

-

-

0

Net loss before income taxes

-66,246

-61,376

-8,943

Income taxes

0

0

0

Net loss

-66,246

-61,376

-8,943

Dividends on redeemable preferred interests

-

-

2,480

Net loss attributable to common shares/ members' interests

-

-

-11,423

Comprehensive loss

-66,246

-61,376

-11,423

Net loss per share - basic and diluted (in dollars per share)

-2.61

-2.96

-

Weighted-average number of common shares outstanding - basic and diluted (in shares)

25,356

20,725

-